Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

• Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012 Dec; 53(12):2383-9.
  View in: PubMed
• Noel MS, Friedberg JW, Barr PM. Novel agents in mantle cell lymphoma. Best Pract Res Clin Haematol. 2012 Jun; 25(2):191-200.
  View in: PubMed
• Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin Immunol. 2012 Mar; 142(3):237-42.
  View in: PubMed
• Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant. 2012 Jul; 47(7):924-33.
  View in: PubMed
• Carter SJ, Bernstein SH, Friedberg JW, Barr PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011 Nov; 35(11):e223-4.
  View in: PubMed
• Dao H, Barr PM, Honda K. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. J Am Acad Dermatol. 2011 Jun; 64(6):e123-5.
  View in: PubMed
• Barr PM, Friedberg JW. Getting to the heart of the problem in treating diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1166-7.
  View in: PubMed
• Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biol Blood Marrow Transplant. 2011 Jul; 17(7):970-8.
  View in: PubMed
• Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 2010 Sep; 17(9):1381-91.
  View in: PubMed
• Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL. Cytometry B Clin Cytom. 2010 Mar; 78(2):115-22.
  View in: PubMed
• Caimi PF, Barr PM, Berger NA, Lazarus HM. Non-Hodgkin's lymphoma in the elderly. Drugs Aging. 2010 Mar 1; 27(3):211-38.
  View in: PubMed
• Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol. 2009 Aug; 84(8):484-7.
  View in: PubMed
• Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol. 2009 Oct; 147(1):89-96.
  View in: PubMed
• Rong YP, Barr P, Yee VC, Distelhorst CW. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochim Biophys Acta. 2009 Jun; 1793(6):971-8.
  View in: PubMed
• Barr PM, Lazarus HM. Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. Curr Opin Oncol. 2008 Sep; 20(5):502-8.
  View in: PubMed
• Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest. 2007 Dec; 25(8):766-75.
  View in: PubMed
• Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B. Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leuk Lymphoma. 2007 Oct; 48(10):1940-9.
  View in: PubMed
• Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat. Neurosci Lett. 1997 Jul 18; 230(2):81-4.
  View in: PubMed